Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma

NCT07691476 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT07691476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07691476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
February 1, 2029
Enrollment
48 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

patients with locally advanced or metastatic but resectable clear cell renal cell carcinoma